There are considerable evidences that the TGF-β/Smad signaling pathway plays a critical role in organ fibrosis, and that the TGF-β receptor and its mediators importantly regulate the organ fibrosis process (Figure 1). TGF-β was first identified as a multifunctional cytokine in the early 1980s, and it is deemed as the transforming growth factors β1 (TGF-β1), β2 (TGF-β2), and β3 (TGF-β3) in mammals. TGF-β1 is the fully-researched member of the transforming growth factor family and is an integral part in tissue fibrosis. This work focuses on the roles of TGF-β1 in the TGF-β/Smad signaling pathway (De Oliveira et al., 2021). TGF-β1 is mainly expressed in endothelial, haematopoietic, and connective tissue cells, where it activates fibroblasts and promotes the synthesis of ECM (Meng et al., 2016). TGF-β2 acts as an indispensable cytokine, similar to TGF-β1, to regulate the cell proliferation, differentiation, migration, and death. Meanwhile, it is a key growth factor in development of fibrogenesis in myofibroblasts (De Oliveira et al., 2021). In addition, TGF-β2 deficiency can affect the epithelial-mesenchymal interactions, cell growth, extracellular matrix production, and tissue remodeling, leading to multi-organ defects (Sanford et al., 1997). TGF-β3 exerts a key role in normal development of the maxilla and lung while involving in epithelial-mesenchymal transition (EMT), cell growth, apoptosis, differentiation, ECM production, and remodeling using an environment-dependent and tissue-specific manner (Kaartinen et al., 1995; Chakrabarti et al., 2020). In addition, TGF-β is secreted as an inactive ligand, which consists of a latency-associated peptide (LAP) and a maturation peptide. LAP is primarily to keep the TGF-β protein in an inactive state and to prevent it from interacting with its receptor. Binding between the TGF-β protein and the LAP can be disrupted by various stimuli such as reactive oxygen species (ROS), integrins, proteases, and metalloproteinases, thereby releasing mature TGF-β protein. Then, the active TGF-β can interact with the receptors of intracellular signaling pathways (Yu et al., 2022).

TGF-β receptors include transforming growth factor-β type I receptor (TGFβRI), transforming growth factor-β type II receptor (TGFβRII), and transforming growth factor-β type III receptor (TGFβRIII). TGF-β1 can bind directly to the TGFβRII receptor, and TGFβRII can recruit and activate the TGFβRI after binding of TGFβRII to TGF-β by phosphorylating the GS structural domain in the TGFβRI (Hachana and Larrivée, 2022). In addition, TGFβRIII increases the bioavailability of TGF-β signaling to TGF-β receptors by transferring TGF-β to its signaling receptor (Yu et al., 2022). In addition, Smad proteins have been extensively studied as key intracellular effectors of TGF-β, playing the role of transcription factors (Meng et al., 2016). The Smad classical signaling pathway is mediated by the Smad protein family of related receptors, which contains eight members in humans (Smads1-8). Besides, it can be divided into three subgroups, namely receptor-activated Smads for Smad2/3, and Smad1/5/8, co-mediator Smad for Smad4, and inhibitory Smads for Smad6 and Smad7 (Luo, 2022). Smad2/3 can be phosphorylated and activated by TGFβRI receptor, and then the phosphorylated Smad2/3 can combine with Smad4, forming a heterotrimer complex and transferring it to the nucleus to regulate the transcription of target genes (Wang et al., 2017). Smad7 is a repressive Smad, and is regulated by the level of phosphorylated Smad3. Moreover, Smad7 competes with Smad3 and Smad2 for the binding site of TGFBR1, thereby promoting TGF-β1/Smad signaling (Mallikarjuna et al., 2022). The Smad non-classical signaling pathways can be triggered by the binding of TGF-β1 and TGFBR2, including p38 mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK), and Nuclear factor of κB (NF-κB) signaling pathways (Chen and Chang, 2022). The above non-classical signaling pathways will be discussed in Section 2.

TGF-β is one of the drivers of fibrosis in most organs. As reported, members of the TGF-β family played important roles in many processes related to cardiac pathophysiology, including cardiac repair, hypertrophy, fibrotic remodelling, fibroblast activation, and ECM deposition (Lovelock et al., 2005; Bagchi et al., 2016; Shinde et al., 2017). Moreover, TGF-β, a key cytokine in fibrotic events, can stimulate the fibroblast activations, including fibroblast to myofibroblast differentiation, collagen synthesis, and ECM protein deposition (Bagchi et al., 2016). Besides, it can induce the expression of a-SMA which is a marker of myofibroblast maturation (Shinde et al., 2017). In addition, TGF-β can inhibit the matrix metalloproteinase activity by producing more matrix metalloproteinase inhibitors, thus reducing the ECM degradation, aggravating deposition, and accelerating the development of fibrosis (Lovelock et al., 2005). Notably, pulmonary arterial hypertension (PAH) increases the endothelial-mesenchymal transition (EndMT) and collagen production, thus promoting the development of cardiac fibrosis. TGF-β family plays a major role in the development and progression of PAH, and is an important regulator in pulmonary vascular remodeling and inflammation, cardiac hypertrophy, and cardiac fibrosis (Ol et al., 2018). Therefore, it is reasonable to assume that TGF-β has an important role in the process of cardiac fibrosis.

TGF-β1, one of the isoforms of TGF-β, is most widely distributed in the mammalian tissues. TGF-β1 plays a vital role in pathological fibrosis and can trigger the development of tissue fibrosis, especially cardiac fibrosis, so it is upregulated in cardiac fibrosis patients and animal models (Nicin et al., 2022). As exhibited in the response to cardiac injury, TGF-β1 can activate the non-fibroblasts, including cardiomyocytes, endothelial cells, and immune cells, thereby conversing the activated fibroblasts and myofibroblasts (Nicin et al., 2022). Moreover, TGF-β1 binds to the TGFβR1 receptor and then activate the Smad2/3 protein, thus leading to collagen production (Lee et al., 2020). Besides, TGF-β1 induces autophagy, and conversion of cardiac fibroblasts to myofibroblasts can be inhibited by inhibiting autophagy (Gupta et al., 2016). In addition, TGFβ2 has been shown to regulate the expression of ECM proteins through the classical and non-classical Smad signaling pathways (McDowell et al., 2013). In contrast, TGF-β3, an important factor in cardiovascular development, mediates the pathological process of CVDs such as cardiomyopathy. In addition, TGF-β3 together with ncRNAs regulate the development of renal cardiac fibrosis in mice (Liu et al., 2022a). Interestingly, not only are the three isoforms of TGF-β involved in the development of cardiac fibrosis, but TGFβR1 and TGFβR2 are integral in the progress of cardiac fibrosis. Conditional deletion of TGFBR1 from fibroblasts significantly attenuates the pressure overload-induced cardiac hypertrophy and enhanced the ventricular function (Khalil et al., 2017). In addition, deletion of TGFBR1 ameliorates the cardiac dysfunction, cardiac hypertrophy, and collagen deposition induced by MI (Chen et al., 2022). The upregulation of TGFBR2 is closely associated with HG-induced cardiac fibrosis, while its downregulation improves the HG-induced proliferation, differentiation, and collagen accumulation of human cardiac fibroblast (HCF) (Li et al., 2016). It has been confirmed that specific ablation of TGFBR2 in myofibroblasts can block the TGFβ signaling in activated fibroblasts, thereby lowering the risks of cardiac fibrosis and cardiac hypertrophy (Meng et al., 2018). Therefore, TGF-β-related factors are closely associated with the cardiac fibrosis, and targeting and regulating the expressions of TGF-β-related factors may be important and effective to treat the cardiac fibrosis.

Smad2 and Smad3 are typical transcription factors downstream of the TGF-β signaling pathway, share a similar structure, possess highly homologous amino acid sequences, but exhibit different roles in tissue repair and fibrosis (Meng et al., 2016). Smad3 is a key mediator of TGF-β signaling in ECM production and tissue fibrosis, and Smad3 deficiency in downstream of the TGF-β signaling pathway alleviate the cardiac fibrosis, enhances the cardiac compliance, and insulates diabetic mice from cardiac fibrosis (Dong et al., 2021; Tuleta and Frangogiannis, 2021). Moreover, Smad3 can specifically reduce myocardial collagen content by inducing fibroblasts, thus being conductive to maintaining the ECM synthesis in the heart (Khalil et al., 2017). Meanwhile, Smad3 deficiency may promote the progression of PAH and cardiac fibrosis (Li et al., 2021a). It has also been shown that Smad3-specific deficiency in fibroblasts, rather than Smad2-specific deficiency, can greatly inhibit the cardiac fibrosis in infarcted myocardium (Huang et al., 2019). In contrast, Smad2 is activated in the TGF-β-stimulated fibroblasts and the infarcted myofibroblasts, whereas myofibroblast-specific Smad2 deficiency can temporarily attenuate the post-infarct remodelling (Huang et al., 2019). Fibroblast-specific Smad2 deficiency exhibits no effects on myocardial collagen content, suggesting the little role of Smad2 signaling in activating the fibroblast repair program (Khalil et al., 2017).

Smad4, encoded by the Smad4 gene, is an intracellular transcriptional mediator of the TGFβ signaling pathway, so it can interact with Smad2/3 in cells and mediate the TGF-β signaling pathway (Li et al., 2022b). In addition, Smad4, as the only Co-Smad identified in mammals, mediates the signals from TGF-β and bone morphogenetic protein (BMP) signaling pathways and helps them shuttle into the nucleus (Kamato et al., 2013). Activated peroxisome proliferator-activated receptor ? (PPARγ) retards the development of cardiac fibrosis, which can be inhibited by TGF-β1 by enhancing the binding of Smad4 and histone deacetylase 1 (HDAC1) and weakening the binding of HDAC3 to the PPARγ promoter in cardiac fibroblasts (Gong et al., 2011). Smad4 signaling can induce the apoptosis in cardiomyocytes and specific deletion of Smad4 in cardiomyocytes leads to cardiac hypertrophy, aggravating the myocardial fibrosis (Wang et al., 2005). Similar to the aforementioned contents, Smad4 is lowly expressed in CHF patients and CH model animals, while its upregulation can inhibit the progression of CHF and CH, which in turn can attenuate the progression of myocardial fibrosis (Wang et al., 2022). Thus, Smad4 plays a key role in cardiac fibrosis and inhibited Smad4 may alleviate the cardiac fibrosis by inhibiting the activity of Smad3-responsive promoter.

TGF-β1 can exert the biological effects through the activation of Smad2 and Smad3. While the activation is negatively regulated by Smad7, indicating that Smad7 acts as an antagonist in TGF-β signaling and thus exerts an anti-fibrotic effect (Hu et al., 2017). According to the relevant researches, Smad7 expression is downregulated in cardiac fibrosis in diabetic cardiomyopathy (DCM) rats, and the high glucose-induced cardiac fibrosis could be alleviated by promoting the expression (Meng et al., 2019). Similarly, the elevated TGF-β1 expression and reduced Smad7 expression are observed in fibrotic tissues of hypertensive rats, whereas overexpressed Smad7 inhibits the HCFs being differentiated into myofibroblasts, thereby attenuating the cardiac fibrosis (Xiao et al., 2020). Moreover, Smad7 expression is upregulated in MI-induced fibroblasts, and its conversion to myofibroblasts is associated with the dependence on Smad3 signaling. Simultaneously, Smad7 over-expression can weaken myofibroblast transformation and reduce collagen type I (Col-I) and fibronectin synthesis, while not affecting the collagen type III (Col-III) levels (Humeres et al., 2022). Thus, it may be an important potential target to promote Smad7 expression for the treatment of cardiac fibrosis.

TGF-β acts in cardiac fibrosis by activating the TGF-β/Smad classical signaling pathway and by regulating non-classical signaling pathways, such as p38MAPK, JNK, ERK, and NF-κB, thereby affecting the progression of cardiac fibrosis. MAPKs are a large family of kinases associated with important cellular functions, including extracellular signal-regulated kinases (ERK1/2), c-JunN-terminal kinases (JNK1, 2, and 3), and p38 MAPKs (p38α, β, γ, and δ) (Turner and Blythe, 2019). As reported, p38MAPK played a key role in the regulation of fibrosis. Moreover, inhibited p38MAPK can inhibit TGF-β-induced Smad2/3 phosphorylation and a-SMA expression, and reduce the pressure overload-induced cardiac hypertrophy and fibrosis in the left ventricle (Turner and Blythe, 2019). Besides, the role of the JNK signaling pathway in fibrosis is confirmed in numerous evidences. For example, interleukin 22 (IL-22) can further increase TGF-β1-induced collagen synthesis in vitro, which can be restricted by inhibitors of the JNK pathway. This work implies that IL-22 may promote fibrosis in vitro by activating the JNK signaling pathway. TGF-β1 also can increase the phosphorylation levels of ERK1/2 in fibroblasts, and the inhibition of ERK expression blocks collagen gene expression in cardiac fibroblasts (Yang et al., 2015). Thus, by inhibiting the factors involved in the MAPK signaling pathway, the progression of cardiac fibrosis can be delayed. Similar to the researches above, NF-κB activation plays a key role in the progression of cardiac fibrosis, for example, AngII induces the NF-κB activation and promotes the cardiac fibroblasts proliferation and collagen synthesis, while cardiac fibrosis can be alleviated effectively by inhibiting the NF-κB activation and nuclear translocation (Gupta et al., 2016; Zhou et al., 2021).

The ncRNAs are a class of genes with limited or without protein-coding capacity, representing 60% of human transcripts. ncRNAs were previously considered to be the “dark matter” of the genome (Kapranov et al., 2010). However, the important regulatory functions of ncRNAs in numerous biological processes, such as cell proliferation and adhesion, apoptosis, angiogenesis, and human migration, were gradually revealed in the last decade (Beermann et al., 2016).

The ncRNAs can be classified into small ncRNAs (sncRNAs, 18-200 nt), lncRNAs (>200 nt), and circRANs with a unique loop structure, based on the 200 nt cut-offs of their mature transcript length (Bian et al., 2021). The small ncRNAs can be divided into small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), miRNAs, and piRNAs (Pinho et al., 2022). In the following introduction, miRNAs, lncRNAs, and circRNAs are focused. The miRNAs are a broad family of sncRNAs with approximately 18–25 nucleotides in length, which are primarily involved in the gene regulation at the post-transcriptional level and target at the specific mRNAs by binding to the 3′UTR of mRNAs in full or partial complementarity (Gebert and MacRae, 2019). LncRNAs are a group of ncRNAs with more than 200 nucleotides in length and multiple regulatory roles (Mercer et al., 2009), with biogenesis similar to mRNAs. lncRNAs are transcribed by RNA polymerase II, followed by the capping in the 5′region and the polyadenylation in the 3′region (Yang et al., 2022). In addition, lncRNAs are present in almost all organisms, represent a high proportion of RNAs in complex organisms, and are expressed at different levels in different tissues (Zhang and Wang, 2022). The circRNAs are a new type of ncRNAs widely existed in animals and other organisms, and a special closed loop can be formed by the reverse splicing between downstream splice donors and upstream splice acceptors (Guo et al., 2014). As indicated by the researches, circRNAs played multiple roles in different subcellular compartments, such as transcriptional activation, post-transcriptional regulation, translation, and protein interactions (Li et al., 2018). Besides, circRNAs can further participate in protein mediation by regulating transcription via the competitive sponge-like miRNAs (Lin et al., 2022).

Cardiac fibrosis is one of the major causes of poor remodelling in HF after MI, thus prevention and reversal of cardiac fibrosis are essential for the treatment of CVD (González et al., 2018). Increasing studies on the structural domains of ncRNAs suggest that the important roles of various miRNAs in cardiac fibrosis after MI are realized by regulating the TGF-β/Smad signaling pathway. The miR-130a is downregulated in infarcted myocardium and hypoxia-induced cardiac fibroblasts, and its over-expression can reduce the size of the infarcted region and attenuate the cardiac impairment. This action mechanism may be related to the regulation of the activity of TGF-β/Smad signaling and the inhibition of the conversion of cardiac fibroblasts to myofibroblasts by the direct targeting of TGFβR1 (Feng et al., 2022). Similarly, upregulation of miR-328 was evident in MI mouse hearts and cardiac fibroblasts, and knockdown of miR-328 inhibited cardiac fibrosis in mice after MI. Moreover, TGFβRIII serves as a direct target of miR-328, and miR-328 over-expression can target and inhibit TGFβRIII, thereby indirectly activating the TGF-β1 signaling pathway, and promoting the collagen production (Du et al., 2016). Similarly, miR-21 expression was upregulated in MI mouse myocardial tissue and AngII-treated cardiac fibroblasts, and knockdown of miR-21 partially inhibited the expression of TGF-β and Smad2/3. Furthermore, Spry1 is one of the target genes of miR-21, and inhibition of its expression reverses the effect of knockdown on TGF-β signaling and promoted the myofibroblast transformation (Li et al., 2020a). Therefore, by targeting and regulating the miR-21-Spry1 axis, new insights into the treatment of cardiac fibrosis after MI can be provided. As exhibited in recent clinical research, miR-205-3p expressions were greatly downregulated in the plasma of MI patients, and miR-205-3p over-expression obviously inhibited the TGF-β1-induced cardiac fibroblast fibrosis (Qiao et al., 2021).

Cardiac fibrosis plays an important role in progression of various CVDs, including MI, atrial fibrillation (AF), and pressure overload-induced cardiac hypertrophy. In addition, it may lead to the reduced cardiac diastolic and systolic function later, possibly developing into HF finally. Some miRNAs can perfect cardiac function by modulating the TGF-β/Smad signaling pathway, thereby improving pressure-load-induced cardiac fibrosis. According to Zhang et al. (Zhang et al., 2018a), miR-323a-3p was discovered to be upregulated in the transverse aortic constriction (TAC)-induced cardiac tissues and the Ang II-treated rat cardiac fibroblasts. Besides, over-expression greatly increased the expressions of Col-I, Col-III, TGF-β, matrix metallopeptidase (MMP) 2, and MMP9 and enhanced the cardiac fibrosis by targeting the induction of the TIMP3-TGF-β pathway. Moreover, miR-26a expression was reduced in plasma and myocardial tissue of hypertensive cardiac fibrosis rats. While, transfection of miR-26a mimics significantly attenuate the expressions of Col-I, Col-III, MMP2, and TGFβRI in the AngII-induced cardiac fibroblasts, indicating that miR-26a inhibited the proliferation of cardiac fibroblasts. Besides, enhancer of zeste homolog 2 (EZH2), connective tissue growth factor (CTGF), and Smad4 are proven to exist at binding sites to miR-26a. The miR-26a can directly target CTGF and Smad4, thereby reducing collagen production and ECM deposition, and inhibiting cardiac fibroblasts proliferation via the EZH2/p21 pathway as well (Zhang et al., 2020a). Similarly, miR-29b is lowly expressed in both AngII-induced fibrotic hearts and cardiac fibroblasts, while the over-expression of miR-29b can prevent AngII-induced cardiac fibrosis and cardiac dysfunction by blocking the TGF-β/Smad3 signaling pathway, with the therapeutic potential for hypertensive heart disease (Zhang et al., 2014).

EndMT is a cellular transdifferentiation program, in which endothelial cells partially lose their endothelial properties and acquire mesenchymal-like characteristics, thereby promoting the development of cardiac fibrosis. Partial miRNAs improve the endothelial dysfunction and inhibit EndMT by blocking the TGF-β/Smad signaling pathway, which makes for the inhibition of cardiac fibrosis development (Ding et al., 2021). According to Ding et al., the miR-195-5p expression is upregulated in DCM rat myocardium and HG-induced human umbilical vein endothelial cells (HUVEC), and the inhibition of miR-195-5p reduces the EndMT in DCM rats and HG-induced EndMT in HUVEC. Moreover, Smad7, a negative regulator of TGF-β1 signaling, acts as a direct target of miR-195-5p, and can mediate the process of cardiac fibrosis in DCM. The silencing miR-195-5p and the promoting smad7 expression can inhibit the activation of TGF-β1/smad signaling pathway, thereby blocking EndMT and attenuating cardiac fibrosis in DCM (Meng et al., 2019; Ding et al., 2021). Similar to the researches above, miR-21 expression was upregulated in the myocardium of Type I diabetic (T1DM) mice, and the inhibition of miR-21 expression can suppress the expression of inhibitory fibrosis markers and alleviate the EndMT in the hearts of T1DM mice. Besides, as indicated by the Western blotting, Smad7 is obviously downregulated in T1DM mice, while p-Smad2 and p-Smad3 are greatly upregulated. Moreover, by inhibiting miR-21 and up-regulating Smad7 expression, the activation of p-Smad2 and p-Smad3 pathways in the hearts of T1DM mice could be blocked, thereby inhibiting EndMT activation and cardiac fibrosis (Li et al., 2020b).

AF is a common clinical arrhythmia. Cardiac fibrosis, as one of the pathogeneses of AF, seriously affects the progression of AF. Simultaneously, as prove by numerous evidences, miRNAs can activate and inhibit the development of cardiac fibrosis by blocking the TGF-β/Smad signaling pathway (Lai et al., 2022). For example, miR-10a inhibits AF-induced cardiac fibrosis by blocking the TGF-β1/Smads signaling pathway, thereby reducing the proliferation of cardiac fibroblasts, inhibiting the collagen formation, and reducing the atrial structural remodelling (Li et al., 2019a). The miR-29b is lowly expressed in AF rat atrial tissues. By promoting its expression, atrial fibrosis and AF in rats can be attenuated, which may be related to miR-29b by targeting TGFβRI and inhibiting the activation of the Smad2/3 signaling pathway (Han et al., 2022). Furthermore, miR-135b is lowly expressed in AF patients, isoproterenol (ISO)-induced rat models, and in vitro rat cardiac fibroblasts (RCFs). Whereas, TGF-βR1, TGF-βR2, and Smad2 are upregulated as their target gene expression. By promoting miR-135b expression, it can inhibit TGF-βR1, TGF-βR2, and Smad2 expression. These findings indicated that miR-135b exerted antiatrial fibrosis effects in vitro and in vivo by the inhibition of the TGF-β/Smads signaling pathway, thus providing a potential approach for the prevention and treatment of human AF (Wang et al., 2021a).

TGF-β induces collagen deposition in the ECM, and some miRNAs inhibit collagen production by regulating the TGF-β/Smad signaling pathway, thereby inhibiting ECM deposition, and alleviating cardiac fibrosis. Xiao et al. (Xiao et al., 2021) discovered that miR-1202 promoted the proliferation, differentiation, and collagen synthesis of HCFs by activating the TGF-β1/Smad2/3 signaling pathway, and downregulated the nNOS by binding to target sites in its mRNA. While, nNOS protected HCFs from TGF-β1-induced differentiation and collagen synthesis via the TGF-β1/Smad2/3 pathway. Thus, transfection of miR-1202 significantly increased the Col-I, Col-III, and a-SMA expressions as well as the Smad2/3 phosphorylation levels, thereby increasing ECM deposition. Furthermore, miR-29a is closely associated with cardiac fibrosis in HCM patients. Activation of ET1 signaling in cardiomyocytes increases ROS production and stimulates TGFβ expression, while miR-29a inhibits TGFβ-induced elastin (ELN) and collagen expression in cardiac fibroblasts, thereby suppressing the process of cardiac fibrosis (Roncarati et al., 2014).

TGF-β1 is an important regulator in the development of tissue fibrosis, and some miRNAs can inhibit the development of cardiac fibrosis by suppressing the expression of TGF-β1 (Stawowy et al., 2004). The protein levels of αSMA, Col-I, and POSTN in mouse heart tissue and the secreted collagen levels in cell culture supernatants increase obviously in response to TGFβ1 stimulation. In contrast, over-expression of miR-675 could reverse the TGFβ1-induced remodelling and the proliferation of mouse cardiac fibroblasts by targeting TGFβR1 (Wang et al., 2019a). Similarly, there were negative correlation between miRNA-663 and TGF-β1 expression in endomyocardial myocardial biopsies from patients with cardiac fibrosis, while over-expression of miRNA-663 resulted in the decreased expression of the cardiac fibrosis markers plasminogen activator inhibitor-1 (PAI-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) (Wu et al., 2019). MiR-30c expression is downregulated in the atrial samples from AAC model rats and in the TGF-β1-stimulated RCFs, whereas miR-30c over-expression inhibited TGF-β1-induces proliferation, differentiation, migration, and ECM synthesis in cardiac fibroblasts, by directly targeting TGFβRII (Xu et al., 2018). Besides, a high NaCl diet can also induce cardiac fibrosis, low miR-210-5p expression was observed in NaCl-added rat cardiac fibroblasts (NRCFs), while over-expression miR-210-5p reversed the upregulated levels of collagen I, a-SMA, and TGF-β1 in NRCFs by targeting TGFβR1, thereby attenuating cardiac fibroblasts activation and ameliorating cardiac fibrosis (Zhao et al., 2021).

Some miRNAs promote the development of cardiac fibrosis, by activating the TGF-β/Smad signaling pathway. Zhang et al. (2022a) verified that there was a positive correlation between miR-208b and miR-21 and the expressions of TGF-β1 and Smad3. The miR-208b/miR-21 promoted the development of cardiac fibrosis by activating the TGF-β1/Smad3 signaling pathway. Furthermore, in HCFs, miR-216a was able to activate the TGF-βRI/Smad2 signaling pathway, thereby reducing the collagen production and the a-SMA protein expression in the activated HSC through negative regulation of Smad7 expression (Tao et al., 2019).

Cardiac fibrosis is one of the major pathological features of diabetic cardiomyopathy. Yang and Zhao, (2022) presented that miR-30a-5p expression was downregulated in myocardial tissue and HG-treated cardiac fibroblasts of diabetes mellitus (DM) rats. Moreover, miR-30a-5p over-expression reduced Smad2 levels, inhibited collagen formation in HG-stimulated cardiac fibroblasts and DM rats. In addition, decreased HG induced proliferation of cardiac fibroblasts, thereby lowering the collagen deposition and thus delaying the progression of cardiac fibrosis in diabetic cardiomyopathy.

PAH pathology involves ECM remodeling in cardiac tissue, which accelerates the progression of cardiac fibrosis. Connolly et al. reported that miR-1-5p and TGF-βR1 were inversely expressed in the RV of MCT-treated rats, and transfection with miR-1-5p mimics significantly lowered the TGF-βR1 in vitro, It suggests that miR-1 causes cardiac hypertrophy by targeting TGF-βR1 and reducing TGF-β signaling, thereby resulting in cardiac hypertrophy [ 86].

In addition to regulating the classical signaling pathways such as TGF-β/Smad in cardiac fibrosis, miRNAs can also participate in the cardiac fibrosis by mediating some non-classical signaling pathways. For example, HG greatly increased the expression of TGFβ1, IL-1β factors, and phosphorylated NF-κB activity. Smad7, a target of miR-150-5p, whose expression is upregulated, inhibits the NF-κB activity and IL-1β production, and suppresses the progression of cardiac fibrosis by inhibiting the TGF-β1/Smad signaling pathway. Thus, it can inhibit TGF-β1/Smad-induced cardiac fibrosis and NF-κB-associated cardiac inflammation by silencing miR-150-5p and up-regulating Smad7 expression, thereby ameliorating the HG-induced cardiac fibroblasts injury (Che et al., 2020a).

In addition, MAPK (ERK1/2, p38MAPK, and JNK) signaling pathways are activated during cardiac fibrosis. The miR-327 expression is investigated to be upregulated in TAC-induced cardiac fibrotic tissue and Ang II-induced cardiac fibroblasts, and the inhibition of miR-327 expression restrains the TAC-induced ERK1/2, p38MAPK, and JNK phosphorylation levels, thereby attenuating the cardiac fibrosis (Ji et al., 2018). Similarly, miR-143-3p is highly expressed in human and animal myocardial infarcted hearts and in TGFβ1-induced human cardiac fibroblasts. SPRY3 is a target gene of miR-143-3p, its downstream ERK, JNK, and p38MAPK signaling pathways are involved in the process of cardiac fibrosis, and the silencing SPRY3 promotes ECM by regulating the MAPK pathway over-accumulation. Thus, miR-143-3p directly targets SPRY3 by activating the p38MAPK, ERK, and JNK signaling pathways, which in turn regulates the biological functions of HCFs such as proliferation, migration, and transformation (Li et al., 2019b). The miR-223 is highly expressed in activated fibroblasts, and promotes their proliferation, migration, and differentiation. While the silencing miR-223 inhibits TGF- β1-induced expression of collagen I, collagen III, and a-SMA proteins, and the over-expression of miR-223 and downregulation of its target recombinant Ras GTPase activating protein 1 (RASA1) promote the phosphorylation of MEK1/2, ERK1/2, and AKT in cardiac fibroblasts, indicating that miR-223 can promote proliferation, migration, and differentiation of cardiac fibroblasts by down-regulating RASA1 expression and activating the renin-angiotensin system (RAS) signaling pathway, thereby aggravating cardiac fibrosis after MI (Liu et al., 2018a). Similarly, miR-378 over-expression inhibited cardiac fibrosis during the cardiac adaptation phase of pressure overload, and restrained the phosphorylation of p38MAPK and Smad2/3 activated by mechanical overload. Moreover, miR-378 inhibited the p38MAPK and Smad2/3 signaling pathways by directly targeting MAPK kinase 6 (MKK6), thereby suppressing the pressure overload-induced cardiac Fibrosis (Yuan et al., 2018). The miR-1468-3p increasing in both the senescent healthy hearts and the patients with sudden cardiac death suffering from primary cardiac fibrosis can enhance the cellular senescence and collagen deposition by promoting TGF-β1-p38 signaling and exerting a dual role (Lin et al., 2020).

Furthermore, the extent of fibrosis depends on the balance between pro-fibrotic and pro-inflammatory signaling. NF-κB is a major determinant of the inflammatory process, and it can promote the transcription of several pro-inflammatory genes, including TNF-α, IL-1β, and IL-6. Adriamycin induces ROS production, and triggers the TGF-β pathway, thereby activating the conversion of cardiac fibroblasts to myofibroblasts. While, using Ant34a (miR-34a inhibitor) in the treatment can greatly reduce NF-κB, IL-6, and TNF-α levels in the hearts of adriamycin-induced animals, and then decrease the Col-I expression and collagen deposition (Piegari et al., 2020) (Table 1).

PAH usually causes right ventricular dysfunction, which is closely associated with cardiac fibrosis. Increased expression of type I and III collagen and MMP2/9 in the PAH group, as reported by Tang et al. (2022) suggested that PAH induced myocardial fibrosis in rats, whereas miR-325-3p overexpression attenuated myocardial fibrosis in PAH rats. In addition, dual-luciferase and bioinformatics reported that miR-325-3p exhibited binding sites to human epididymis protein 4 (HE4), and miR- 325-3p inhibited cardiac fibroblast fibrosis by targeting and regulating HE4. In addition, miR-1 was reported to exhibit an increased expression in the hypoxia-induced RV of PAH model rats, inhibiting the expressions of collagen I, collagen III, a-SMA, and CTGF, the further study revealed that expressions of p-phosphatidylinositol 3-kinase (PI3K) and p-AKT are upregulated in hypoxia-induced cardiac fibroblasts and are reversed by the transfected miR-1 antagomiR (Liu et al., 2021a). It means that miR-1 involves in the PAH-induced right ventricular hypertrophy and fibrosis by regulating the PI3K/AKT signaling pathway.

Dysregulation of LncRNAs and TGF-β is an important trigger of cardiac fibrosis. In recent decades, their link has been investigated and has exhibited that lncRNAs and TGF-β can interact in several mechanisms of cardiac fibrosis onset and progression. For example, as indicated by the research of Guo et al. (2022), the over-expression of lncRNA H19 which was a competing endogenous RNA for miR-29a/b-3p, greatly promoting the cardiac fibroblasts proliferation and collagen production. In contrast, the over-expression of miR-29a/b-3p could reverse the effects of H19 on cardiac fibroblasts activity and collagen production by targeting vascular endothelial growth factor A (VEGFA) and TGF-β. Moreover, the over-expression of lncRNA HOXA11-AS promoted the expression of TGFβ1 signaling pathway and downstream proteins, and enhanced the proliferation and migration of cardiac fibroblasts by enhancing the TGFβ1 activity, thereby promoting the progression of cardiac fibrosis (Wang et al., 2019b). Besides, expression of lncRNA FAF was downregulated in both Ang-induced heart tissue and cardiac fibroblasts of rat, and elevating its expression can inhibit the phosphorylation levels of Smad2/3 (Sun et al., 2020). It suggests that the over-expression of FAF inhibited the proliferation and transformation of fibroblasts and then relieve the collagen production and cardiac fibrosis. In another study, expressions of lncRNA MHRT were found to be elevated in TGF-β1-treated mouse heart tissues and cardiac fibroblasts. Over-expression of MHRT promoted the collagen production and proliferation of cardiac fibroblasts and reduced the expression of miR-3185. In addition, siMHRT could reverse the inhibitory effect of TGF-β1 on miR- 3185 expression. Thus, MHRT aggravated the myocardial collagen deposition by regulating miR-3185 expression, thereby exacerbating the cardiac fibrosis after MI (Lang et al., 2021).

TGF-β3 is a member of multifunctional peptide superfamily, regulates cell growth and differentiation, and exerts a special role in tissue fibrosis (Liu et al., 2022b). For example, Liu et al. reported that Vgll3 could positively regulate the expression of the key pro-fibrotic factor TGF-β3 and the downstream factor smad2/4. As demonstrated by dual luciferase reporter and Western blotting experiments, Vgll3 overexpression could promote the activation and proliferation of cardiac fibroblasts in mice. Such phenomenon was counteracted by TGF-β3, suggesting that Vgll3, a member of lncRNA, could promote the progression of cardiac fibrosis by activating the TGF-β3-related pathways (Stawowy et al., 2004). Being different from the above studies, lncRNA nuclear enriched abundant transcript 1 (NEAT1) is closely associated with the progression of lung, liver, and kidney fibrosis (Wang et al., 2019a; Wang et al., 2021b; Zhao et al., 2022). As reported, NEAT1 was significantly expressed in both HF patients and TAC-induced HF mouse models, inhibition of its expression attenuated the TGF-β1-induced cardiac fibrosis, GSK126 (an EZH2 inhibitor) weakened TGF-β1-induced downregulation of Smad7 expression and upregulation of p-Smad2/3, and upregulation of Smad7 reversed the cardiac fibrosis caused by NEAT1 over-expression (Zhang et al., 2020b). The lncRNA Cfast is highly expressed in heart tissue of MI mouse, and Cfast competitively interacts with COTL1 to prevent COTL1 from binding to TRAP1, thereby enhancing the formation of the TRAP1/Smad2/Smad4 complex and thus activating the TGF-β signaling pathway (Zhang et al., 2020c). Therefore, inhibiting the Cfast in the heart can prevent the pathological fibrotic remodelling and improve the cardiac function. LncRNA CRNDE is an RNA specifically expressed in heart tissues of human and mouse, and its over-expression inhibits the differentiation of cardiac fibroblasts to myofibroblasts, which may be related to the blocking of transcriptional activation of the TGF-β/Smad3 signaling pathway (Zheng et al., 2019). Moreover, LncRNA mannose-inhibitable adhesin-T7 receptor (MIAT) is upregulated in cardiac tissues of the MI mouse model, and knockdown of MIAT inhibits the collagen production and cardiac fibroblasts proliferation, thereby suppressing interstitial fibrosis by a mechanism related to MIAT sponging miR-24, and thus regulating Furin/TGF-β1 expression (Qu et al., 2017). Similarly, LncRNA MIAT attenuates its inhibitory effect on IL-17 by sponging miR-22-3p, thus leading to cardiac fibrosis (Qu et al., 2017). lncRNA MALAT1 expression is upregulated in diabetic mice and HG-induced fibroblasts, and acts as a sponge for miR-141, thereby promoting the upregulation of TGF-β1, p-Smad2, p Smad3, NLRP3, caspase-1, IL-18, and IL-1β. While over-expression of miR-141 can reduce the expressions of the above factors (Che et al., 2020b).

MI can induce excessive secretion of ECM by cardiac fibroblasts, and activate and remodel myocardium, thus leading to cardiac fibrosis and cardiac dysfunction (Travers et al., 2016). According to Luo et al. (2020), lncRNA 554 was upregulated in both cytoplasm and nucleus of the MI-induced cardiac fibroblasts, while the silencing 554 significantly downregulated the expression of TGF-β1 and Smad3. Such findings suggest that the inhibition of lncRNA 554 expression attenuates the cardiac fibrosis and enhance the cardiac function in MI mice. Similarly, lncRNA Ang362 was highly expressed in MI-induced cardiac fibrosis rats and RCFs, and promoted the TGF-β1-induced collagen expression by suppressing Smad7 expression, thereby aggravating the cardiac fibrosis (Chen et al., 2020a) (Table 2).

Similar to the role of miRNAs, LncRNAs involves in the progression of cardiac fibrosis by regulating PI3K-Akt, MAPK, and other signaling pathways in addition to the classical signaling pathway of TGF-β. For example, EndMT plays an important role in pathophysiological processes such as myocardial ischemia-reperfusion, MI, diabetic cardiomyopathy, and fibrosis. There is an example: EndMT plays an important role in pathophysiological processes such as myocardial ischemia-reperfusion, myocardial infarction, diabetic cardiomyopathy, and fibrosis; and TGF-β-induced EndMT can be attenuated by knocking down the LINC00961 by a mechanism related to activation of phosphatase and tensin homolog (PTEN) expression and inhibition of PI3K, AKT, and mammalian target of rapamycin (mTOR) (Hu et al., 2022). mTOR, as a PI3K- Akt downstream gene, mainly regulates the cardiac fibrosis by affecting the expressions of pro-fibrotic factors. A study revealed that lncRNA CFAR expression is upregulated in MI-induced fibrosis mouse models and TGF-β-induced fibrotic cell models. The mechanism analysis suggested that lncRNA CFAR, a ceRNA of miR-449a-5p, promotes the Lysyl oxidase-like protein 3 (LOXL3) expression, and overexpression of which may elevate the mTOR expression, aggravating the cardiac fibrosis (Zhang et al., 2022b). Additional evidence suggests that PTEN is a major regulator of the PI3K/Akt pathway, and inhibited PTEN promotes the ECM deposition and myocardial fibrosis in mice (Yuan et al., 2019). LncRNA GAS5 is lowly expressed in cardiac fibrotic tissues and activated cardiac fibroblasts, and its overexpression can inhibit the cardiac fibroblast proliferation. In addition, miR-21 can play a pro-fibrotic role in multiple organs, and lncRNA GAS5 can act as a sponge for miR-21 to inhibit the PTEN/MMP2 expression and the progression of cardiac fibrosis (Tao et al., 2017).

The ERK1/2 signaling pathway, a family member of MAPK and in the downstream of TGF-β1, can be activated during the progression of cardiac fibrosis (Kong et al., 2014). Linc00092, a glycolysis-related lncRNA and expressed mainly in cardiac tissues and cardiac fibroblasts, inhibits the TGFβ1-induced HCF activation by suppressing glycolysis, and its overexpression significantly and consistently attenuates the phosphorylation of ERK and subsequently inhibits the ERK activation and HCF activation (Chen et al., 2020b). Shi et al. (2022) showed that silencing lncRNA-HCG18 in cardiac fibroblasts significantly promoted the hsa-miR-133a expression, inactivated the ERK1/2 pathway and inhibited the cell proliferation of cardiac fibroblasts by downregulating the EGFR expression. It suggests that lncRNA-HCG18 can exert an regulatory effect in progression of cardiac fibrosis through the hsa-miR-133a/ERK/EGFR axis. Similarly, lncRNA H19 expression is upregulated in cardiac fibrotic tissues and activated fibroblasts, while overexpression of DUSP5 abrogates the pro-proliferative effect of H19 in cardiac fibroblasts by a mechanism associated with inhibition of ERK1/2 phosphorylation (Tao et al., 2016). In addition, MAPK1 has been reported to involve in various biological processes including myocardial fibrosis, and can be inhibited by exosomes containing LINC00636 by elevating the miR-450a-2-3p expression, thus alleviating the cardiac fibrosis in patients with AF (Liu et al., 2021b).

The main feature of cardiac fibrosis is the activation, proliferation, and transformation of cardiac fibroblasts. Some circRNAs can regulate the miRNAs expression and the TGF-β/Smad signaling pathway, thus playing a key role in the pathogenesis of cardiac fibrosis. According to Li et al. (2020c), circRNA heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) increased and mainly expressed in cardiac fibroblasts in heart after ischemia. Meanwhile, it limited the differentiation of cardiac fibroblasts into myofibroblasts by miR-216-5p-SMAD7-mediated degradation of TGF-β1, thus becoming a potential new target for the treatment of cardiac fibrosis after ischemia. In addition, CircRNA NFIB has been found to be lowly expressed in heart tissue of MI mouse and TGF-β-treated cardiac fibroblasts, and its expression inhibits the cardiac fibroblasts proliferation by a mechanism related to sponging miR-433 to upregulate the AZIN1 and JNK1 and inhibit the cardiac fibroblasts proliferation (Zhu et al., 2019).

Cardiac fibrosis leads to the expression of a-SMA by activated myofibroblasts, and promotes the formation of ECM proteins (COL1A1 and COL3A1). Some circRNAs can regulate TGF-β/Smad expression, and inhibit fibrotic proteins expression, thereby suppressing the onset and progression of cardiac fibrosis. For example, as presented by Ni et al. (2019), circRNA HIPK3 was highly expressed in AngII-treated cardiac fibroblasts and mouse heart tissue, and promoted cardiac fibroblasts proliferation, migration, and cardiac fibrosis by sponging miR-29b-3p and up-regulating a-SMA, COL1A1, and COL3A1 expressions. Similar to the above studies, circRNA HIPK3 expression is upregulated in hypoxia-induced cardiac fibroblasts, and silencing circHIPK3 inhibits the cell proliferation and migration. The bioinformatics and immunofluorescence reports indicate that circRNA HIPK3 can bind to miR-152-3p to inhibit the proliferation of cardiac fibroblasts and expressions of ColI, ColIII, and TGF-β2 after hypoxic stimulation. Therefore, circHIPK3 is a molecular regulator during the cardiac fibrosis through miR-152-3p/TGF-β2 signaling (Liu et al., 2020). Similarly, Zhou and Yu (2017) discovered that circRNA_010567 was greatly expressed in diabetic mouse myocardium and AngII-induced cardiac fibroblasts, and regulated the expression of TGF-β1 and fibrosis genes by acting as a sponge for miR-141.

Atrial fibrosis plays an important role in the progression of AF. The dysregulation of some circRNAs may promote AF, and thus becomes a potential regulator and biomarker of persistent AF. A clinical research indicated that circRNA_0004104 was significantly downregulated in the plasma of patients with persistent AF, and that it could negatively regulate the expression of MAPK and TGF-β1. This evidence suggests that circRNA_0004104 could promote cardiac fibrosis by targeting MAPK and TGF-β signaling pathways, and that elevating the circRNA_0004104 0004104 expressions can be a potential strategy to treat the f cardiac fibrosis and persistent AF (Gao et al., 2021). In the above section, we summarized the mechanism of different non-coding RNA regulating TGF signaling pathways in cardiac fibrosis, and they played an important role in the process of cardiac fibrosis (Table 3; Figure 2).

According to the previous studies, there are many herbal formulas for inhibiting the progression of cardiac fibrosis by regulating the TGF-β/Smad signaling pathway. As indicated by one research, Fu fang Zhen Zhu Tiao Zhi (FTZ) could greatly downregulate the expressions of a-SMA, Col1A2, Col-III, and CTGF, thereby inhibiting the ECM deposition and the cardiac fibrosis. Moreover, FTZ also attenuated the proliferation and migration of cardiac fibroblasts by restraining the activation of the TGFβ1-Smad2/3 signaling pathway and suppressing the collagen synthesis, indicating that FTZ possessed great therapeutic potential in the treatment of cardiac fibrosis (Zhang et al., 2022c). Similar to the researches above, the Heart-Protective Soup can inhibit the expressions of Col-Ⅰ and Col-Ⅲ in adriamycin-induced dilated cardiomyopathy, in addition to reducing the expressions of TGF-β1 and Smad3, thereby promoting cardiac function and reducing cardiac fibrosis (Sun et al., 2017). In another research, the Kangxian Formula (KXF) was found to inhibit the AngII-induced proliferation and migration of cardiac fibroblasts in addition to reducing the expression of TGFβRI, TGFβRII, Smad2, Smad3, and Smad4 in cardiac fibroblasts, suggesting that KXF exerted a protective effect against cardiac fibrosis by blocking the activation of the TGF-β signaling pathway (Chen et al., 2021a). According to Su et al. (2020), Si-Miao-Yong-An Decoction (SMYAD) could decrease the expressions of a-SMA, Col, and ColIII, thereby reducing the ECM deposition. Moreover, SMYAD could block TGF-β1/Smad7 expression by suppressing the expressions of TGF-β1, Smad2, and Smad3 and upregulating the Smad7 expression. Thereby, progression of cardiac fibrosis can be inhibited by blocking TGF-β1/Smad pathway activation. Besides, Tao Hong Si Wu Tang (THSWD), a traditional formula consisting of Tao Ren, Hong Hua, Shu Di, Bai Shao, Chuan Xiong, and Angelica sinensis, was found to inhibit cardiac fibroblasts proliferation and collagen expression by restraining the activation of TGFβR1/Smad signaling pathway in a dose-dependent manner in a post-MI mouse model. These data indicated that THSWD inhibited cardiac fibroblasts proliferation and collagen expression, alleviated cardiac fibrosis, and improved cardiac function in mice after MI, by blocking activation of the TGFβR1/Smad signaling pathway (Tan et al., 2021). Similarly, in a model of radiation cardiac injury constructed by local irradiation of the precordial region at 25 Gy, Huangqi Shengmai Yin (HSY) was discovered to inhibit the epithelial proliferation, cardiac fibroblasts proliferation, and collagen deposition in irradiated tissues by blocking the binding of TGFβ1 to its receptor. Besides, it can maintain the balance between collagen synthesis and degradation by reversing the effects of radiation on MMP14 and TIMP1 expression and the balance between collagen synthesis and degradation (Cella et al., 2015; Gu et al., 2019) (Table 5).

In recent years, under the guidance of the theoretical system of TCM, researchers have actively searched for the Chinese patent medicines that exert anti-cardiac fibrosis effects by regulating the TGF-β/Smad signaling pathway. For example, in a rat model of ascending aortic stenosis (AAS), Qi Shen Yi Qi Pill (QSYQP) was proven to be able to inhibit the expression of TGFβRII and Smad3, and up-regulate the expression of Smad7, thereby suppressing ECM deposition. Moreover, QSYQP also inhibited overburden pressure-induced cardiac fibrosis, with the mechanism associated with the inhibition of cardiomyocyte apoptosis and TGF-β1/Smad signaling pathway (Anwaier et al., 2022). It was shown that upregulation of the TGF-β1/Smad3 pathway may increase the susceptibility to differentiation of cardiac fibroblasts in MI and TAC rats. Treatment with Danqi Soft Capsule (DQ) and Guanxin Shutong Capsule (GXST) could decrease the expressions a-SMA, TGF-β1, and p-Smad3 greatly. It clarifies that DQ and GXST reversed the myofibroblast formation by regulating the TGF-β/Smad3 signaling pathway, thereby improving cardiac fibrosis in MI and TAC rats (Pan et al., 2021; Ma et al., 2022). Huo Xin Pill not only inhibited the ISO-induced proliferation, migration, and differentiation of cardiac fibroblasts, but also restrained the proliferation and migration of cardiac fibroblasts by suppressing TGF-β1/smads signaling pathway activation, thus exerting an anti-cardiac fibrosis effect (Peng et al., 2021). Furthermore, the Chinese patent medicine Qingxuan Jiangya decoction (QDG) was first used for the treatment of hypertension. According to a recent in vivo research, a medium dose of QDG (0.9 g/kg/day) greatly reduced the left ventricular ejection fraction, improved the cardiac function in SHR rats by reducing α, and restrained the differentiation and proliferation of cardiac fibroblasts by reducing the SMA expression and proliferating the cell nuclear antigen (PCNA). However, in vitro experiments presented that 6.25 and 12.5 μg/mL of QDG could inhibit the AngII-induced activation of the TGF-β1/Smad2/3 signaling pathway, thereby effectively reducing collagen deposition and inhibiting interstitial fibrosis (He et al., 2020; Chen et al., 2021b). HF is the swollen stage of various CVDs, and cardiac fibrosis can accelerate the deterioration of cardiac function in HF patients. As demonstrated by a recent ex vivo research, QSG inhibited the proliferation and differentiation of cardiac fibroblasts, and reduced the collagen deposition in the infarct margins of HF rats, by inhibiting the expression of TGF-β1 and Smad3 and up-regulating the expression of Smad7 (Guo et al., 2016; Zeng et al., 2019). Wu et al. (2021) observed 140 patients with IHF treated with Shexiang Tongxin Dropping Pills (STDP) )and found that the expressions of TGF-β1 and MMP2 were lower while the TIMP2 expression was higher when compared with the control group. The results revealed that STDP can not only regulate the dynamic balance of MMP2 and TIMP2 to maintain ECM homeostasis but also inhibit the TGF-β1 to impair the differentiation, migration, and proliferation of cardiac fibroblasts, which in turn hindered the cardiac fibrosis. Such results could be found in Table 6; Figure 3.

In the above sections, the research progress related to TCM and ncRNAs in cardiac fibrosis through modulation of TGF-β/Smad signaling pathways, respectively, is presented. These three aspects are not isolated but crosstalk each other, and TCM is also involved in the progression of cardiac fibrosis through modulation of ncRNAs and classical and non-classical TGF-β/Smad signaling pathways. A previous study reported that tanshinone IIA (TSN) protected the myocardium and inhibited cardiomyocyte hypertrophy. miR-205-3p and TGF-β1 were significantly downregulated after a two-week treatment with TSN. Transfecting miR-205-3p in cardiac fibroblasts could elevate the TGF-β1 expression and Col1a1 and Col3a1 were upregulated in TGF-β1-induced cardiac fibroblasts, which can be reversed by TSN treatment. It suggested that TSN enhances the cardiac function and attenuates the cardiac fibrosis after MI by upregulating miR-205-3p and thereby inhibiting TGF-β1 levels (Qiao et al., 2021). Furthermore, TGF- β1 is a key factor in progression of myocardial fibrosis, which promotes ECM deposition and thus plays an important role in cardiac remodeling. Zhang et al. found that resveratrol (RSV) inhibited the TGF-β1-induced cardiac fibroblasts proliferation and collagen secretion by a mechanism associated with silencing miR-17 or overexpression of Smad7, thus providing a new experimental basis for the efficacy of RSV in treating myocardial fibrosis (Zhang et al., 2018c). Another study showed that berberine can effectively inhibit left ventricle hypertrophy and cardiac fibrosis and improve the cardiac function (Liao et al., 2018). Zheng et al. (2020) investigated the effect of berberine on miR-29b expression in pressure-overloaded hypertrophic myocardium, and pre-applied it to treat the cardiac fibrosis. Finally, they confirmed that berberine (100 mg/kg/day) inhibited myocardial hypertrophy and fibrosis in stress overload models by up-regulating the expression of miR-29b and down-regulating the expression of its target genes. A study showed that Hong Hua (HH) improved cardiac function and ventricular remodeling and prevented the cardiac fibrosis in patients with ischemic cardiomyopathy., Ting Li Zi (TLZ) was proved to play an inhibitory effect on myocardial hypertrophy and fibrosis and corrected HF (Chen et al., 2019; Yu et al., 2019). Wang et al. (2020) observed the inhibitory effect of HH-TLZ on cardiac fibrosis in CHF mice after MI, and revealed that compared to the model group, CTL-TLZ (2.0 mg/mL) could upregulate the miRNA-22 and TGFβ-1 in myocardial tissue. In addition, the CTL-TLZ presented a role of downregulating COL1A1, COL3A1, and TGFβ-1 and upregulating miRNA-22 in cardiac fibroblasts, thus inhibiting the proliferation and collagen synthesis of cardiac fibroblasts. It suggests that the CTL-TLZ has an inhibitory effect on cardiac fibrosis in CHF mice after MI, and the mechanism may be related to the activation of miRNA-22/TGFβ-1 signaling pathway in fibroblasts.

Furthermore, TCM can regulate ncRNAs involved in the progression of cardiac fibrosis through TGF-β non-classical signaling pathways, such as the MMP signaling pathway. Gu et al. (2022) reported that Long Sheng Zhi Capsule (LSZ) inhibited the AngII-induced cardiac hypertrophy and fibrosis and rescued the expression of miR-150-5p treated with AngII; While miR 150-5p overexpression ameliorated the AngII-induced cardiac hypertrophy and fibrosis by attenuating the cardiac hypertrophy and fibrosis through MMP14 (Table 7; Figure 3).